- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
 |
Hypertension
According to the \"2018 China Cardiovascular Disease Report\", the number of cardiovascular deaths in my country accounts for more than 40% of the overall death of residential diseases, which is first, higher than tumor and other diseases. According to the existing data, the number of cardiovascular diseases in my country is approximately 24 million, of which the high blood pressure population is about 245 million. Studies have shown that high blood pressure is also an important risk factor for other cardiovascular diseases, 79.8% of stroke related to hypertension, especially cerebral hemorrhage; control blood pressure can effectively reduce 40-509% of stroke at normal levels.
Hypertensive individualization
According to \"China's Nutrition and Chronic Disease Report (2016)\" data shows that the national hypertension has 51.6%, the treatment rate is 45.8%, and the control rate is only 16.8%. In response to the treatment of medicinal treatment, the hypertension control rate is low in patients, and the diet and lifestyle have not improved, and it is also an important factor. At present, there is a wide variety of hypertension, and it is necessary to choose a suitable drug according to the patient's own gene polymorphism. At the same time, it will be controlled in a timely manner, and the blood pressure can be controlled in the normal range.
Tianlong overall solution
Tianlong hypertension self-medication microsection solution Based on the microsection technique of special ligase and fluorescent capture probe, the micro-measurement reagent and Fascan fluorescent quantitative analyzer of Tianlong independently developed can quickly obtain high blood pressure individualization. Seven genes for medication: CYP2D6 * 10, CYP2C9 * 3, ADRB1 (1165g> c),
AGTR1 (1166A> C), ACE (/ D), NPPA (2238T> C), CYP3A5 * 3 for guiding five types of hypertensive drugs: beta receptor blockers, angiotensin I receptor antagonists, blood vessels Tight tension-converting enzyme inhibitors, diuretics, calcium ion antagonists.
Guide and norms related to hypertensive individualization drug
In 2013, the National Health Statistical Committee released the \"Notice of the Printing and Distributing Medical Institution Clinical Test Project Catalog (2013 Edition), which explicitly uses genes CYP2D6, CYP2C9, ADRB1, AGTR1, ACE detection of hypertension in the detection of drugs in drugs. Molecular biology Test items.
In 2015, the Safety Commission issued a \"drug metabolic enzyme and drug action target genetic testing technical guide (trial)\", it is recommended to detect the related gene CYP2D6, CYP2C9, ADRB1, ACE of hypertension, and sampling, testing, reporting and Quality control conducted a corresponding specification.
In 2017, the Quality Administration Committee of the Safety Metaphore Commission and the Chinese Medical Association of Hypertension (2nd Edition) \", which clearly proposed: Different individuals have a huge difference between drug reactions, and hypertension should consider drugs. Genomic factors.
Hypertensive individual medication detection genes and related drugs
Detection gene site | Related drug |
CYP2D6 * 10 | β-receptor blocker: 乐 乐, 美托尔, Cavallo, Altenol, Prolol, hydrochloric acid ornament, etc. |
ADRB1 (1165g> C) | |
CYP2C9 * 3 | Vascular tension II receptor antagonist (ARB): chlorostean, Betan, Canrtisartan, valsartan, Mishatan, etc. |
AGTR1 (1166A> C) | |
ACE (I / D) | Vascular tension rehabilitase inhibitor (ACEI): Bena Purli, Fosinopri, Enabili, Mi Duri, Perindopril, Remuri, etc. |
NPPA (2238T> C) | Diuretics: chlorothiazide, hydrochlorothiazide, benzylfluorothiazine, chlorothionic, etc. |
CYP3A5 * 3 | Calcium ion antagonist (CCB): nifedipine, nonoccoss, Lasi, amloblore, Sili equality |
CYP2D6 * 10 | Calcium ion antagonist (CCB): nifedipine, Niger earth, amlodipine equality |
